Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.

BMC genomic data - 5 Dec 2024

Mahajan Rashmi, Tyagi Anuj Kumar

Abstract excerpt

BACKGROUND: Tuberculosis (TB) patients undergoing anti-tuberculosis treatment often face serious adverse drug reactions, such as hepatotoxicity. Genetic variants of the N-acetyltransferase 2 (NAT2) gene have been linked to an increased risk of these toxic events. OBJECTIVE: This study aims to provide a comprehensive evaluation of the evidence linking NAT2 genetic variants to anti-tuberculosis drug-related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemical and Drug Induced Liver Injury

Share to Genetic Variation

Share to Genotype

Share to Pharmacogenetics

Share to Tuberculosis

Source

Open in PubMed Open full text

Identifiers

PMID: 39639188
DOI: 10.1186/s12863-024-01286-y
PMCID: PMC11622454

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.PMID 39639188Read ↗

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.Semantic proximity Read ↗

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.Semantic proximity Read ↗

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.Semantic proximity Read ↗

Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.Semantic proximity Read ↗

NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity.Semantic proximity Read ↗

Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidenceSemantic proximity Read ↗

NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Semantic proximity Read ↗

NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.Semantic proximity Read ↗

NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.